
    
      This is a multicenter, non-randomized, open, single-arm, phase IIa trial investigating the
      security and effectiveness of Keynatinib in patients with advanced non-small cell lung cancer
      (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR
      inhibitors.
    
  